- Home
- HOFT vs BEATW Comparison
HOFT vs BEATW Comparison
Compare HOFT & BEATW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOFT
- BEATW
- Stock Information
- Founded
- HOFT 1924
- BEATW N/A
- Country
- HOFT United States
- BEATW United States
- Employees
- HOFT N/A
- BEATW 13
- Industry
- HOFT Home Furnishings
- BEATW Retail: Computer Software & Peripheral Equipment
- Sector
- HOFT Consumer Discretionary
- BEATW Technology
- Exchange
- HOFT Nasdaq
- BEATW Nasdaq
- Market Cap
- HOFT N/A
- BEATW N/A
- IPO Year
- HOFT 1999
- BEATW 2021
- Fundamental
- Price
- HOFT $15.71
- BEATW $0.54
- Analyst Decision
- HOFT
- BEATW
- Analyst Count
- HOFT 0
- BEATW 0
- Target Price
- HOFT N/A
- BEATW N/A
- AVG Volume (30 Days)
- HOFT 22.0K
- BEATW N/A
- Earning Date
- HOFT 09-05-2024
- BEATW N/A
- Dividend Yield
- HOFT 5.86%
- BEATW N/A
- EPS Growth
- HOFT N/A
- BEATW N/A
- EPS
- HOFT 0.12
- BEATW N/A
- Revenue
- HOFT $402,257,000.00
- BEATW N/A
- Revenue This Year
- HOFT N/A
- BEATW N/A
- Revenue Next Year
- HOFT $13.67
- BEATW N/A
- P/E Ratio
- HOFT $129.01
- BEATW N/A
- Revenue Growth
- HOFT N/A
- BEATW N/A
- 52 Week Low
- HOFT $13.09
- BEATW N/A
- 52 Week High
- HOFT $27.15
- BEATW N/A
- Technical
- Relative Strength Index (RSI)
- HOFT 55.61
- BEATW N/A
- Support Level
- HOFT $15.13
- BEATW N/A
- Resistance Level
- HOFT $16.18
- BEATW N/A
- Average True Range (ATR)
- HOFT 0.51
- BEATW 0.00
- MACD
- HOFT 0.05
- BEATW 0.00
- Stochastic Oscillator
- HOFT 65.57
- BEATW 0.00
About BEATW Heartbeam Inc.
HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.